Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can aspirin and advil cause stomach bleeding?Is it possible to expedite vascepa's application processing?Which forms should i complete for lipitor's program?How does diet impact vascepa's results?Are there any restrictions on lipitor and berries?
See the DrugPatentWatch profile for tremfya
How does Tremfya work compared with Skyrizi? Both drugs block interleukin-23 (IL-23), a cytokine that drives inflammation in psoriasis and psoriatic arthritis. Tremfya (guselkumab) and Skyrizi (risankizumab) bind the p19 subunit of IL-23, interrupting the same signaling pathway, so their mechanisms are nearly identical. What clinical trial results show the biggest differences? In head-to-head trials, both agents produced similar rates of clear or almost-clear skin (PASI 90) at week 16—roughly 70–75 %. Skyrizi showed a modest edge at week 52 in some studies, but the absolute difference was only a few percentage points. Joint responses in psoriatic arthritis were also comparable. How often is each injection given? Tremfya starts with two starter doses four weeks apart, then continues every eight weeks. Skyrizi uses the same starter schedule but switches to every twelve weeks after week 16. The longer Skyrizi interval means four fewer injections per year once maintenance begins. What are the main side-effect differences patients report? Injection-site reactions occur slightly more often with Tremfya. Upper-respiratory infections, headache, and fatigue appear at similar rates for both. Neither drug carries a boxed warning, and rates of serious infection remain low in long-term extension data. Can biosimilars reach the market before patents expire? Tremfya’s composition-of-matter patent expires in 2028; Skyrizi’s runs until 2032. Litigation and regulatory exclusivity could push actual biosimilar entry later for both. [1] When does each drug lose market exclusivity? The FDA granted Tremfya seven-year orphan-drug exclusivity for its initial psoriasis indication, ending in 2024, but additional patents still block biosimilars. Skyrizi’s biologic exclusivity extends to at least 2030. [1] Who manufactures each product and what do they cost? Janssen produces Tremfya; AbbVie produces Skyrizi. Cash prices for a single maintenance dose exceed $10,000 before insurance, with both companies offering copay-assistance programs that can reduce out-of-pocket cost to $5 per dose for eligible patients. [1] DrugPatentWatch.com [1] https://www.drugpatentwatch.com
Other Questions About Tremfya :